Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas
- 1 August 2007
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 57 (2), 201-206
- https://doi.org/10.1016/j.lungcan.2007.03.007
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science
- Smoking Research Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- National Institute of Biomedical Innovation
This publication has 21 references indexed in Scilit:
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersJNCI Journal of the National Cancer Institute, 2000
- Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the BreastThe American Journal of Pathology, 1999
- Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell linesOncogene, 1998
- PTEN mutations in gliomas and glioneuronal tumorsOncogene, 1998
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997